Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s00280-016-2983-0
Published Online: 2016-02-18
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Trafalis, Dimitrios T.
Alifieris, Constantinos
Stathopoulos, George P.
Sitaras, Nikolaos
Text and Data Mining valid from 2016-02-18